Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, New York 10065
Dr. David H. Ilson is an Associate Attending Physician at Memorial Sloan-Kettering Memorial Hospital in New York, New York. He specializes in gastrointestinal oncology. Dr. Ilson is also Associate Member at Memorial Sloan-Kettering Memorial Hospital and an Associate Professor of Medicine at Weill Medical College of Cornell University. In addition to mesothelioma, Dr. Ilson’s clinical expertise is in the areas of gastrointestinal cancers such as colorectal cancer, esophageal cancer, pancreatic cancer, gastric cancer and other gastrointestinal cancers as well as unknown primary tumors. His research focus is research focus is studying new agents to treat advanced disease and evaluating novel agents in combined-modality therapy to treat locally advanced disease.
Dr. Ilson completed his undergraduate training at the University of Connecticut in Farmington , Connecticut . He entered an M.D. and Ph.D. combined degree program at New York University School of Medicine. Dr. Ilson received his Masters Degree and his Ph.D. in Basic Science and a Medical Degree (M.D.) from New York University School of Medicine. He completed his Internship in Internal Medicine at New York University Medical Center Bellevue Hospital, as well as his Residency in Internal Medicine. Dr. Ilson completed his Fellowship at Memorial Sloan-Kettering Cancer Center, in New York, New York. He joined Memorial Sloan-Kettering Cancer Center’s Gastrointestinal Oncology Service in 1992.
Dr. Ilson is a member of the Gastrointestinal (GI) committees of several national clinical research groups including: Cancer and Leukemia Group B (CALGB) and the Radiation Therapy Oncology Group (RTOG). He is also a member of the Upper GI Cancer Guidelines Committee of National Comprehensive Cancer Network (NCCN) and chairman of the Intergroup Esophageal and Gastric Cancer Task Force Committee.
Dr. Ilson has dozens of journal articles to his credit. The list below represents only a few of Dr. Ilson’s journal articles.
Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L, Rusch VW. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007 Dec;2(12):1117-23. PMID: 18090585 [PubMed – in process]
Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol. 2007 Oct 17; [Epub ahead of print] PMID: 17947223 [PubMed – as supplied by publisher]
Ilson DH. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol. 2007 Aug 1;25(22):3188-90. No abstract available. PMID: 17664464 [PubMed – indexed for MEDLINE]